initial public offerings (IPOs) trading on American exchanges

Saturday, February 15, 2014

NephroGenex (NRX) began trading on the NASDAQ on 11 February 2014

Description

NephroGenex, Inc. is a United States-based drug development company focusing on novel therapies for kidney disease. The Company has developed Pyridorin (pyridoxamine dihydrochloride), it targets diabetes-induced carbonyl and oxidative chemistries that are a principal causative factor in the development of diabetic nephropathy and other diabetic complications. It is conducting a new Phase 2b clinical trial (PYR-210) that is evaluating the safety and efficacy of Pyridorin in slowing the progression of overt nephropathy in patients with type 2 diabetes.

Address

4401 Research Commons Building Suite 290, 
79 T.W. Alexander D P.O. Box 14188
RESEARCH TRIANGLE PARK, NC 27709-4188
United States

Key stats and ratios

Q3 (Sep '13)2012
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-965.40%-347.63%
Return on average equity--
Employees3

No comments:

Post a Comment